Real-world outcomes in patients with AML and MDS treated with Azacitidine

被引：0
|
作者：
Prusak, E. [1 ]
Lawes, M. [2 ]
Collins, A. [2 ]
机构：
[1] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England
[2] Norfolk & Norwich Univ Hosp, Haematol, Norwich, Norfolk, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
AML; Azacitidine; mds;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-PO-0
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [31] Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy
    Acker, Fabian
    Chromik, Joerg
    Tiedjen, Emily
    Wolf, Sebastian
    Vischedyk, Jonas B.
    Makowka, Philipp
    Enssle, Julius C.
    Kouidri, Khouloud
    Sebastian, Martin
    Steffen, Bjoern
    Oellerich, Thomas
    Serve, Hubert
    Neubauer, Andreas
    Schaefer, Jonas A.
    Bittenbring, Joerg T.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (05) : 623 - 630
  • [32] A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m+AML in Japan
    Kiguchi, Toru
    Sakurai, Masaya
    Tanaka, Yusuke
    Kuramoto, Kazuyuki
    Kado, Yuki
    Sawada, Sono
    Mitomi, Takeshi
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (11) : 1513 - 1522
  • [33] Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
    Platzbecker, U.
    Wermke, M.
    Radke, J.
    Oelschlaegel, U.
    Seltmann, F.
    Kiani, A.
    Klut, I-M
    Knoth, H.
    Roellig, C.
    Schetelig, J.
    Mohr, B.
    Graehlert, X.
    Ehninger, G.
    Bornhaeuser, M.
    Thiede, C.
    LEUKEMIA, 2012, 26 (03) : 381 - 389
  • [34] Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine
    Breccia, Massimo
    Salaroli, Adriano
    Loglisci, Giuseppina
    Alimena, Giuliana
    ANNALS OF HEMATOLOGY, 2013, 92 (03) : 411 - 412
  • [35] Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy
    Chikashi Yoshida
    Takeshi Kondo
    Tomoki Ito
    Masahiro Kizaki
    Kazuhiko Yamamoto
    Toshihiro Miyamoto
    Yasuyoshi Morita
    Tetsuya Eto
    Yuna Katsuoka
    Naoki Takezako
    Nobuhiko Uoshima
    Kazunori Imada
    Jun Ando
    Takuya Komeno
    Akio Mori
    Yuichi Ishikawa
    Atsushi Satake
    Junichi Watanabe
    Yoshiko Kawakami
    Tetsuo Morita
    Ikue Taneike
    Masahiko Nakayama
    Yinghui Duan
    Belen Garbayo Guijarro
    Alexander Delgado
    Cynthia Llamas
    Hitoshi Kiyoi
    International Journal of Hematology, 2022, 116 : 89 - 101
  • [36] Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system
    Okamoto, Haruya
    Inoue, Yu
    Miyashita, Akihiro
    Kawaji-Kanayama, Yuka
    Chinen, Shotaro
    Fujino, Takahiro
    Tsukamoto, Taku
    Shimura, Yuji
    Mizutani, Shinsuke
    Kaneko, Hiroto
    Kuwahara-Ota, Saeko
    Fuchida, Shin-ichi
    Nishiyama, Daichi
    Hirakawa, Koichi
    Uchiyama, Hitoji
    Uoshima, Nobuhiko
    Kawata, Eri
    Kuroda, Junya
    KOTOSG investigators
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (03) : 323 - 332
  • [37] Real-World (RW) Outcomes With Venetoclax (VEN) in Patients With Acute Myeloid Leukemia (AML) From COTA, a US RW Evidence Database
    Stein, Eytan
    Hodzic, Sejla
    Owusu, Henry
    Pathak, Dhrubajyoti
    Zhou, Summera
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S288 - S289
  • [38] Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
    T Cluzeau
    C Moreilhon
    N Mounier
    J-M Karsenti
    L Gastaud
    G Garnier
    D Re
    N Montagne
    J Gutnecht
    P Auberger
    J G Fuzibet
    J-P Cassuto
    S Raynaud
    Blood Cancer Journal, 2013, 3 : e155 - e155
  • [39] Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
    Tong, Juan
    Zhao, Na
    Hu, Xing
    Yao, Wen
    Cheng, Yaxin
    Zhou, Li
    Liu, Huilan
    Geng, Liangquan
    Sun, Zimin
    Zheng, Changcheng
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5613 - 5621
  • [40] Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
    Cluzeau, T.
    Moreilhon, C.
    Mounier, N.
    Karsenti, J-M
    Gastaud, L.
    Garnier, G.
    Re, D.
    Montagne, N.
    Gutnecht, J.
    Auberger, P.
    Fuzibet, J. G.
    Cassuto, J-P
    Raynaud, S.
    BLOOD CANCER JOURNAL, 2013, 3 : e155 - e155
12345